• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Prelude Therapeutics Incorporated (Amendment)

    2/12/24 5:30:07 PM ET
    $PRLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRLD alert in real time by email
    SC 13G/A 1 e619249_sc13ga-prelude.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (Amendment No. 1) *

     

    Prelude Therapeutics Incorporated

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    74065P101

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

      

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    (Page 1 of 9 Pages)

     

    __________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

    CUSIP No.

    74065P101

    13G Page 2 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Mgmt, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    4,133,000 (1)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    4,133,000 (1)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,133,000 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.85% (2)

    12.

    TYPE OF REPORTING PERSON*

     

    PN

      

    __________________ 

    (1)Comprised of shares of common stock held by Deerfield Partners, L.P., of which Deerfield Mgmt, L.P. is the general partner.

    (2)Percentage ownership is based on 41,965,472 shares of the Issuer’s voting common stock outstanding, which reflects 54,815,731 shares of the Issuer’s voting and non-voting common stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 (the “Form 10-Q”), less 12,850,259 shares of the Issuer’s non-voting common stock that were outstanding as of September 30, 2023, as reported in the Form 10-Q.

          

    CUSIP No.

    74065P101 

    13G Page 3 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Management Company, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    4,133,000 (3)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    4,133,000 (3)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,133,000 (3)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.85% (4)

    12.

    TYPE OF REPORTING PERSON*

     

    PN

     

    __________________

    (3)Comprised of shares of common stock held by Deerfield Partners, L.P. of which Deerfield Management Company, L.P. is the investment advisor.

    (4)Percentage ownership is based on 41,965,472 shares of the Issuer’s voting common stock outstanding, which reflects 54,815,731 shares of the Issuer’s voting and non-voting common stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 (the “Form 10-Q”), less 12,850,259 shares of the Issuer’s non-voting common stock that were outstanding as of September 30, 2023, as reported in the Form 10-Q.

      

     

     

    CUSIP No.

    74065P101 

    13G Page 4 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Deerfield Partners, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    4,133,000

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    4,133,000

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,133,000

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.85% (5)

    12.

    TYPE OF REPORTING PERSON*

     

    PN

     

    __________________  

    (5)Percentage ownership is based on 41,965,472 shares of the Issuer’s voting common stock outstanding, which reflects 54,815,731 shares of the Issuer’s voting and non-voting common stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 (the “Form 10-Q”), less 12,850,259 shares of the Issuer’s non-voting common stock that were outstanding as of September 30, 2023, as reported in the Form 10-Q.

      

     

     

    CUSIP No.

    74065P101 

    13G Page 5 of 9

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    James E. Flynn

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    0

     
    6.

    SHARED VOTING POWER

     

    4,133,000 (6)

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    0

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    4,133,000 (6)

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,133,000 (6)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    9.85% (7)

    12.

    TYPE OF REPORTING PERSON*

     

    IN

     

    __________________

    (6)Comprised of shares of common stock held by Deerfield Partners, L.P.

    (7)Percentage ownership is based on 41,965,472 shares of the Issuer’s voting common stock outstanding, which reflects 54,815,731 shares of the Issuer’s voting and non-voting common stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 (the “Form 10-Q”), less 12,850,259 shares of the Issuer’s non-voting common stock that were outstanding as of September 30, 2023, as reported in the Form 10-Q.

      

    CUSIP No.

    74065P101 

    13G Page 6 of 9

     

    Item 1(a). Name of Issuer:
       
     

    Prelude Therapeutics Incorporated

       
    Item 1(b). Address of Issuer's Principal Executive Offices:
       
     

    200 Powder Mill Road 

    Wilmington, DE 19803

       
    Item 2(a). Name of Person Filing:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P.

       
    Item 2(b). Address of Principal Business Office, or if None, Residence:
       
     

    James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010

       
    Item 2(c). Citizenship:
       
     

    Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships;

     

    James E. Flynn – United States citizen

       
    Item 2(d). Title of Class of Securities:
       
     

    Common Stock

       
    Item 2(e). CUSIP Number:
       
     

    74065P101

         
    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

       
    (a) ☐

    Broker or dealer registered under Section 15 of the Exchange Act.

         
    (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act.
         
    (c) ☐

    Insurance company as defined in Section 3(a)(19) of the Exchange Act.

         
    (d) ☐

    Investment company registered under Section 8 of the Investment Company Act.

         
    (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
         
    (g) ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
         
    (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
         
    (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

    CUSIP No.

    74065P101 

    13G Page 7 of 9

     

    (j) ☐ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
         
    (k) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________________________

     

    Item 4. Ownership.
           

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

           
    (a) Amount beneficially owned**:  
           
     

    Deerfield Mgmt, L.P. – 4,133,000 shares

    Deerfield Management Company, L.P. - 4,133,000 shares

    Deerfield Partners, L.P. - 4,133,000 shares

    James E. Flynn – 4,133,000 shares

           
    (b) Percent of class**:  
           
     

    Deerfield Mgmt, L.P. – 9.85%

    Deerfield Management Company, L.P. – 9.85%

    Deerfield Partners, L.P. – 9.85%

    James E. Flynn – 9.85% 

           
    (c) Number of shares as to which such person has**:  
           
      (i) Sole power to vote or to direct the vote: All Reporting Persons  0
           
      (ii) Shared power to vote or to direct the vote:

    Deerfield Mgmt, L.P. - 4,133,000

    Deerfield Management Company, L.P. - 4,133,000

    Deerfield Partners, L.P. - 4,133,000

    James E. Flynn – 4,133,000 

           
      (iii)

    Sole power to dispose or to direct the disposition of:

    All Reporting Persons - 0
           
      (iv)

    Shared power to dispose or to direct the disposition of:

    Deerfield Mgmt, L.P. - 4,133,000

    Deerfield Management Company, L.P. - 4,133,000

    Deerfield Partners, L.P. - 4,133,000

    James E. Flynn – 4,133,000

      

    **See footnotes on cover pages which are incorporated by reference herein.

        

    CUSIP No.

    74065P101 

    13G Page 8 of 9

     

    Item 5. Ownership of Five Percent or Less of a Class.
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following ☐.

       
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

       
      N/A
       
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

       

    If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       

    If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

       
      See Exhibit B
       
    Item 9. Notice of Dissolution of Group.
       

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

       
      N/A

       
    Item 10. Certifications.
       

    "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a–11."

     

    CUSIP No.

    74065P101 

    13G Page 9 of 9

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    DEERFIELD MGMT, L.P.

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

    Date: February 12, 2024

     

     

     

     

    Exhibit List

     

    Exhibit A. Joint Filing Agreement.

     

    Exhibit B. Item 8 Statement.

     

    Exhibit C. Power of Attorney (1).

     

    (1) Power of Attorney previously filed as Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.

     

     

     

     

    Exhibit A

     

    Joint Filing Agreement

     

    The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Prelude Therapeutics Incorporated shall be filed on behalf of the undersigned.

     

    DEERFIELD MGMT, L.P.

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

     

    DEERFIELD MANAGEMENT COMPANY, L.P.

    By: Flynn Management LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

     

    DEERFIELD PARTNERS, L.P.

    By: Deerfield Mgmt, L.P., General Partner

    By: J.E. Flynn Capital, LLC, General Partner

     

    By: /s/ Jonathan Isler

           Jonathan Isler, Attorney-In-Fact

     

     

    JAMES E. FLYNN

     

    /s/ Jonathan Isler

    Jonathan Isler, Attorney-In-Fact

     

     

     

     

    Exhibit B

     

    Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

     

     

    Get the next $PRLD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRLD

    DatePrice TargetRatingAnalyst
    9/19/2024$5.00Neutral → Buy
    H.C. Wainwright
    6/20/2024$3.00Equal Weight → Underweight
    Barclays
    3/13/2024$7.00Mkt Outperform
    JMP Securities
    2/20/2024$5.00Buy → Neutral
    H.C. Wainwright
    12/19/2023$10.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    11/21/2022$8.00 → $6.00Neutral → Underperform
    BofA Securities
    9/9/2022$19.00 → $11.00Overweight → Equal-Weight
    Morgan Stanley
    7/29/2022$9.00Buy
    Jefferies
    More analyst ratings

    $PRLD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Chemistry Officer Combs Andrew bought $69,250 worth of shares (100,000 units at $0.69), increasing direct ownership by 26% to 480,123 units (SEC Form 4)

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      3/27/25 4:40:54 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Vaddi Krishna bought $467,438 worth of shares (675,000 units at $0.69), increasing direct ownership by 51% to 1,999,296 units (SEC Form 4)

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      3/27/25 4:37:44 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO Vaddi Krishna bought $14,909 worth of shares (20,416 units at $0.73), increasing direct ownership by 2% to 1,324,296 units (SEC Form 4)

      4 - Prelude Therapeutics Inc (0001678660) (Issuer)

      3/24/25 5:03:10 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRLD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Prelude Therapeutics to Participate in Upcoming Healthcare Conferences

      WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June. Jefferies Global Healthcare Conference 2025:On Thursday, June 5, 2025, at 3:10 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. Goldman Sachs 46th Annual Global Healthcare Conference:On Wednesday, June 11, 2025, at 9:20 a.m. ET, Kris, Vaddi, Ph.D., Chief Executive Officer of Prelude will participate in a fireside chat. Live webcasts of the fireside chats can be accessed on the Company's

      6/2/25 7:30:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude's once daily, oral SMARCA2 degrader, PRT7732 is advancing rapidly, and an initial data update is anticipated in the second half of 2025 Current cash runway into the second quarter of 2026 with $103.1 million in cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025  WILMINGTON, Del., May 06, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology company, today reported its financial results for

      5/6/25 4:05:00 PM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prelude Therapeutics to Participate in Citizens Life Sciences Conference

      WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (NASDAQ:PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025. On Wednesday, May 7, 2025, at 11:00 a.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Peggy Scherle, Ph.D., Chief Scientific Officer will participate in a fireside chat. A live webcast of the fireside chat can be accessed on the Company's website under Events and Presentations. The recording will be archived and available on the Compa

      5/1/25 7:30:00 AM ET
      $PRLD
      Biotechnology: Pharmaceutical Preparations
      Health Care